HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glucosamine

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers of joint supplements make products that conform with claimed label amounts, first formally released results of National Nutritional Foods Association's TruLabel program indicate. NNFA Director of Science & Quality Assurance Phillip Harvey, PhD, announced results at the trade group's MarketPlace 2001 in Las Vegas June 8. All 28 glucosamine-only products NNFA purchased at retail passed its testing; glucosamine content was analyzed using capillary electophoresis, and ion chromatography was used to verify the type of glucosamine in the product. A product listing will be available at NNFA's Web site, which is being revamped. Results appear to correspond with those reported by ConsumerLab.com (1"The Tan Sheet" March 13, 2000, p. 7). Other products will undergo TruLabel testing shortly, with CoQ10 supplements to undergo analysis before end of June

You may also be interested in...



Low Chondroitin Levels Due To Poor Quality Control, Cost - ConsumerLab.com

Poor quality control and the high cost of chondroitin are likely to blame for below-label levels of the dietary supplement ingredient found in eight of 25 products examined by ConsumerLab.com, the company reported.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel